PMID- 34114250 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20240403 IS - 1573-6598 (Electronic) IS - 0894-9867 (Print) IS - 0894-9867 (Linking) VI - 34 IP - 4 DP - 2021 Aug TI - Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. PG - 851-863 LID - 10.1002/jts.22696 [doi] AB - Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased attention on sleep in clinical PTSD research, SDs remain difficult to treat. In Phase 2 trials, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been shown to greatly improve PTSD symptoms. We hypothesized that MDMA-assisted psychotherapy would improve self-reported sleep quality (SQ) in individuals with PTSD and be associated with declining PTSD symptoms. Participants in four studies (n = 63) were randomized to receive 2-3 sessions of active MDMA (75-125 mg; n = 47) or placebo/control MDMA (0-40 mg, n = 16) during all-day psychotherapy sessions. The PSQI was used to assess change in SQ from baseline to the primary endpoint, 1-2 months after the blinded sessions. Additionally, PSQI scores were measured at treatment exit (TE) and 12-month follow-up. Symptoms of PTSD were measured using the CAPS-IV. At the primary endpoint, CAPS-IV total severity scores dropped more after active MDMA than after placebo/control (-34.0 vs. -12.4), p = .003. Participants in the active dose group showed more improvement in SQ compared to those in the control group (PSQI total score DeltaM = -3.5 vs. 0.6), p = .003. Compared to baseline, SQ had improved at TE, p < .001, with further significant gains reported at 12-month follow-up (TE to 12-months DeltaM = -1.0), p = .030. Data from these randomized controlled double-blind studies provide evidence for the beneficial effects of MDMA-assisted psychotherapy in treating SDs in individuals with PTSD. CI - (c) 2021 MAPS Public Benefit Corporation. Journal of Traumatic Stress published by Wiley Periodicals LLC on behalf of International Society for Traumatic Stress Studies. FAU - Ponte, Linnae AU - Ponte L AD - Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA. FAU - Jerome, Lisa AU - Jerome L AD - MAPS Public Benefit Corporation, San Jose, California, USA. FAU - Hamilton, Scott AU - Hamilton S AD - Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, California, USA. FAU - Mithoefer, Michael C AU - Mithoefer MC AD - Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA. FAU - Yazar-Klosinski, Berra B AU - Yazar-Klosinski BB AD - MAPS Public Benefit Corporation, San Jose, California, USA. FAU - Vermetten, Eric AU - Vermetten E AD - Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands. AD - ARQ National Psychotrauma Center, Diemen, The Netherlands. FAU - Feduccia, Allison A AU - Feduccia AA AD - Psychedelic Support, Santa Cruz, California, USA. LA - eng GR - Multidisciplinary Association for Psychedelic Studies/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20210610 PL - United States TA - J Trauma Stress JT - Journal of traumatic stress JID - 8809259 RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) SB - IM MH - Combined Modality Therapy MH - Humans MH - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use MH - Psychotherapy MH - Sleep MH - Sleep Quality MH - *Stress Disorders, Post-Traumatic/drug therapy MH - Treatment Outcome PMC - PMC8453707 EDAT- 2021/06/12 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/09/21 CRDT- 2021/06/11 07:05 PHST- 2021/03/19 00:00 [revised] PHST- 2019/12/18 00:00 [received] PHST- 2021/03/22 00:00 [accepted] PHST- 2021/06/12 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/11 07:05 [entrez] PHST- 2021/09/21 00:00 [pmc-release] AID - JTS22696 [pii] AID - 10.1002/jts.22696 [doi] PST - ppublish SO - J Trauma Stress. 2021 Aug;34(4):851-863. doi: 10.1002/jts.22696. Epub 2021 Jun 10.